Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?


Creative Commons License

ÇETİNKALP Ş. , SIMSIR I. Y. , ŞAHİN F. , SAYDAM G. , URAL A. U. , YILMAZ C.

SAUDI PHARMACEUTICAL JOURNAL, vol.23, no.1, pp.14-21, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1016/j.jsps.2013.12.009
  • Title of Journal : SAUDI PHARMACEUTICAL JOURNAL
  • Page Numbers: pp.14-21

Abstract

PPARs are ligand-regulated transcription factors and regulate expression of several gene products. Therefore, PPARs are being studied for their possible contribution to the treatment of cancer, atherosclerosis, inflammation, infertility and demyelinating diseases. Primary AML patients were observed to have significantly elevated PPAR gamma mRNA expression compared to normal peripheral blood or bone marrow mononuclear cells. This study investigated the cytotoxic effects of rosiglitazone maleate, a pure PPAR gamma agonist, in vitro in HL-60 cell line.